Modality
Nanobody
MOA
JAK1i
Target
PCSK9
Pathway
Checkpoint
Wilms
Development Pipeline
Preclinical
~Feb 2012
→ ~May 2013
Phase 1
~Aug 2013
→ ~Nov 2014
Phase 2
~Feb 2015
→ ~May 2016
Phase 3
~Aug 2016
→ ~Nov 2017
NDA/BLA
Feb 2018
NDA/BLACurrent
NCT06232980
247 pts·Wilms
2018-02→TBD·Completed
247 total pts1 indication
Approved
CompletedCurrentUpcoming
Trial Timeline
NDA/BLA
Complet…
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06232980 | NDA/BLA | Wilms | Completed | 247 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| GIL-4361 | Gilead Sciences | Preclinical | PCSK9 | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA | |
| ARG-1924 | Argenx | Preclinical | DLL3 | |
| BMR-8377 | BioMarin | Phase 1/2 | PCSK9 | |
| Capifutibatinib | Incyte | Phase 3 | PCSK9 |